Evidence map›Paper›PMID 30753274›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2019

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

R Barroso-Sousa, W T Barry, H Guo, D Dillon, Y B Tan, K Fuhrman, W Osmani, A Getz, M Baltay, C Dang and 7 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00542451 (A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00542451 phase2completednot on this map

A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2007 to 2022Enrolled406ConditionsBreast Cancer, Carcinoma of the BreastArmsPaclitaxel, Trastuzumab
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

R Barroso-SousaDepartments of Medical Oncology.
W T BarryBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston.
H GuoBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston.
D DillonDepartment of Pathology, Brigham and Women's Hospital, Boston.
Y B TanDepartment of Pathology, Brigham and Women's Hospital, Boston.
K FuhrmanNanostring, Seattle.
W OsmaniDepartments of Medical Oncology.
A GetzDepartment of Pathology, Brigham and Women's Hospital, Boston.
M BaltayDepartment of Pathology, Brigham and Women's Hospital, Boston.
C DangBreast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, New York; Department of Medicine, Weill Cornell Medical Center, New York.
D YardleyTennessee Oncology, Nashville.
B MoyDepartment of Hematology-Oncology, Massachusetts General Hospital, Boston.
P K MarcomDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham.
E A MittendorfDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, USA.
I E KropDepartments of Medical Oncology.
E P WinerDepartments of Medical Oncology.
S M TolaneyDepartments of Medical Oncology. Electronic address: sara_tolaney@dfci.harvard.edu.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USCornell University · USDuke Cancer InstituteMassachusetts General Hospital · USNanostring Technologies (United States) · USTennessee Oncology · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundPrevious data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors. In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics. PATIENTS AND

methodsThe APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. The study included 406 patients with HER2-positive, node-negative breast cancer, measuring up to 3 cm. Exploratory analysis of tumor infiltrating lymphocytes (TIL), programmed death-ligand 1 (PD-L1) expression (by immunohistochemistry), and immune gene signatures using data generated by nCounter PanCancer Pathways Panel (NanoString Technologies, Seattle, WA), and their association with pathological and molecular characteristics was carried out.

resultsOf the 406 patients, 328 (81%) had at least one immune assay carried out: 284 cases were evaluated for TIL, 266 for PD-L1, and 213 for immune gene signatures. High TIL (≥60%) were seen with greater frequency in hormone-receptor (HR) negative, histological grades 2 and 3, as well in HER2-enriched and basal-like tumors. Lower stromal PD-L1 (≤1%) expression was seen with greater frequency in HR-positive, histological grade 1, and in luminal tumors. Both TIL and stromal PD-L1 were positively correlated with 10 immune cell signatures, including Th1 and B cell signatures. Luminal B tumors were negatively correlated with those signatures. Significant correlation was seen among these immune markers; however, the magnitude of correlation did not indicate a monotonic relationship between them.

conclusionImmune profiles of small HER2-positive breast cancers differ according to HR status, histological grade, and molecular subtype. Further work is needed to explore the implication of these findings on disease outcome. CLINICAL

trial registrationclinicaltrials.gov identifier: NCT00542451.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorBreastBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomyMiddle AgedPaclitaxelB7-H1 AntigenBiomarkers, TumorCD274 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPaclitaxelTrastuzumabHER2-postitive breast cancerimmune profilePD-L1 expression, TILstage Itumor-inflamed signature

Identifiers

PMID30753274
PMCPMC8033534
OpenAlexW2911681680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.